This issue discusses the role of neruohumoral modulators in Heart Failure. The role and dosing ACE inhibitor therapy, the relevance of aldosterone antagoinsts, beta blockers, and novel neurohumoral antagonists are explored. Clinical trials and intervenional recommendations are also presented.
1. Neurohormonal Upregulation in Heart Failure (Francis) 2. Neurohumoral Substrate in the Community and in Populations Susceptible to Heart Failure (Ramachandran) 3. Role and Optimal Dosing of ACE Inhibitor Therapy (Deswal) 4. Could Beta-Blockers Precede or Replace ACE-Inhibitors in Heart Failure? (Remme) 5. Relevance of Aldosterone Antagonists: Is There a Need to Readjust Angiotensin Inhibition? (Pitt) 6. Novel Neurohumoral Antagonists (Udelson) 7. Natriuretic Peptides and Remodeling in Heart Failure (Burnett) 8. Pharmacogenomics for Neurohormonal Intervention in Heart Failure (McNamara) 9. Role of Neurohumoral Modulators in Heart Failure with Preserved Systolic Function (Gheorghiade) 10. Neural Endopeptidase Inhibitors and Endothelin Antagonists: Why Did the Clinical Trials Not Demonstrate Beneficial Effects? (Abraham) 11. Should Neurohormonal Intervention Be Recommended in Heart Failure Stage A? (Fonarow) 12. ACE-Inhibitors Only, ARBs Only or Both (Young) 13. Are There Clinically Important Differences Between Beta-Blockers in Heart Failure? (Cleland)
Komentarze (0)
Chwilowo nie możesz polubić tej opinii
Zgłoś komentarz
Czy jesteś pewien, że chcesz zgłosić ten komentarz?
Zgłoszenie wysłane
Twój komentarz został wysłany i będzie widoczny po zatwierdzeniu przez moderatora.